EGFR and breast neoplasm: Targeting proteolytic neoepitopes may serve as an orthogonal “AND” gate for enhancing the therapeutic index, an observation even more clinically important as EGFR/RAS pathway activation is prevalent in breast tumors with poor prognosis.